U.S. military to roll out now EHR system in early 2017

A new electronic health record system for military officials is set to roll out in the beginning of next year, reports Military Times. It was originally scheduled to launch at two military bases in December but was postponed after compatibility and technical issues emerged during early testing.

The system, called MHS GENESIS, is a $4.3 billion upgrade to the military’s current one. It will be launched at Fairchild Air Force Base in Washington in February and will make its way to other locations in June.

“The time we are investing in the program now will help us ensure success in the future, providing the best possible user experience to our beneficiaries and health care providers from day one,” said Stacy Cummings, program executive officer for Defense Healthcare Management Systems.

To read more about the new EHR system, follow the link below:

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup